Lancet Neurology

Papers
(The H4-Index of Lancet Neurology is 86. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 20192161
Neurological associations of COVID-191423
Neuropathology of patients with COVID-19 in Germany: a post-mortem case series915
Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?742
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts644
The characterisation of subjective cognitive decline596
Challenges in the diagnosis of Parkinson's disease453
Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches390
Advances and challenges in stroke rehabilitation390
APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches386
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group379
The global burden of neurological disorders: translating evidence into policy354
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation342
Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues295
2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis293
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial269
Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias251
Myelin-oligodendrocyte glycoprotein antibody-associated disease249
Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria235
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial220
Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial210
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study210
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study207
Interpretation of risk loci from genome-wide association studies of Alzheimer's disease205
New insights into atypical Alzheimer's disease in the era of biomarkers203
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study201
Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia201
Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study200
Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study190
Remyelination in multiple sclerosis: from basic science to clinical translation186
Traumatic brain injury: progress and challenges in prevention, clinical care, and research186
Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial179
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial177
Long-term unsupervised mobility assessment in movement disorders172
Seizure outcome and use of antiepileptic drugs after epilepsy surgery according to histopathological diagnosis: a retrospective multicentre cohort study168
Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study165
The influence of timing of surgical decompression for acute spinal cord injury: a pooled analysis of individual patient data162
An Italian programme for COVID-19 infection in multiple sclerosis157
The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study156
Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-cont155
A case of probable Parkinson's disease after SARS-CoV-2 infection155
Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease144
The neuropsychiatry of Parkinson's disease: advances and challenges140
Neuroinflammation in intracerebral haemorrhage: immunotherapies with potential for translation139
Progress towards therapies for disease modification in Parkinson's disease134
30 years of second-generation antiseizure medications: impact and future perspectives133
Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial132
Monogenic variants in dystonia: an exome-wide sequencing study131
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study126
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials124
Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis123
Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis117
Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis115
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial115
PET imaging of neuroinflammation in neurological disorders115
Strategic infarct locations for post-stroke cognitive impairment: a pooled analysis of individual patient data from 12 acute ischaemic stroke cohorts115
Post-viral effects of COVID-19 in the olfactory system and their implications113
COVID-19 related stroke in young individuals112
Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder110
Evidence-based support for autistic people across the lifespan: maximising potential, minimising barriers, and optimising the person–environment fit109
Functional neurological disorder: new subtypes and shared mechanisms109
Multiple sclerosis progression: time for a new mechanism-driven framework108
Neuromodulation in epilepsy: state-of-the-art approved therapies107
Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial106
Intracranial pressure monitoring in patients with acute brain injury in the intensive care unit (SYNAPSE-ICU): an international, prospective observational cohort study105
Medical management with interventional therapy versus medical management alone for unruptured brain arteriovenous malformations (ARUBA): final follow-up of a multicentre, non-blinded, randomised contr104
Comparison of eight prehospital stroke scales to detect intracranial large-vessel occlusion in suspected stroke (PRESTO): a prospective observational study104
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial104
Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial103
Integrated and patient-centred management of Parkinson's disease: a network model for reshaping chronic neurological care101
Initiation of pharmacological therapy in Parkinson's disease: when, why, and how100
Forecasting seizure risk in adults with focal epilepsy: a development and validation study100
Moyamoya disease: diagnosis and interventions99
Advances in understanding of Rett syndrome and MECP2 duplication syndrome: prospects for future therapies99
Risk of stroke in relation to degree of asymptomatic carotid stenosis: a population-based cohort study, systematic review, and meta-analysis97
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, 95
Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective95
Genetic basis of lacunar stroke: a pooled analysis of individual patient data and genome-wide association studies94
Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study93
Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities92
Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances91
SARS-CoV-2 and the risk of Parkinson's disease: facts and fantasy91
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study90
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial87
Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials87
Ageing without dementia: can stimulating psychosocial and lifestyle experiences make a difference?87
Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment86
Alzheimer's disease associated with Down syndrome: a genetic form of dementia86
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial86
Brain injury after cardiac arrest: from prognostication of comatose patients to rehabilitation86
0.046247959136963